Core Insights - Zhonghui Biotech (02627.HK) experienced a significant stock price increase of 158% on its debut, closing at HKD 33.28 per share, resulting in a total market capitalization of HKD 13.09 billion [1] Company Overview - Zhonghui Biotech focuses on the research, development, manufacturing, and commercialization of innovative vaccines and traditional vaccines using new technological methods [1] - The company has two core products: a quadrivalent influenza virus subunit vaccine and a developing lyophilized human rabies vaccine [1] IPO Performance - The IPO of Zhonghui Biotech was highly successful, achieving over 4,000 times oversubscription in the public offering in Hong Kong, with a total subscription amount exceeding HKD 200 billion [1] - This oversubscription made Zhonghui Biotech the top performer in the 18A biotech sector of the Hong Kong stock market for the year [1]
中慧生物上市首日大涨158%